Journal: Frontiers in Molecular Biosciences

Article Title: A validated LC-ESI-MS/MS assay for simultaneous plasma quantification of 11 antimicrobials to support personalized dosing in critically ill children

doi: 10.3389/fmolb.2026.1745458

Figure Lengend Snippet: Representative chromatograms of double blank sample, IS of each ATB, LLOQ of 11 ATBs (Caspofungin, CAS; Cefazolin, CFZ; Cefmetazole, CMZ; Imipenem, IPM; Linezolid, LZD; Latamoxef, MOX; Meropenem, MEM; Posaconazole, POS; Tigecycline, TIG; Piperacillin, PRL; Voriconazole, VCZ; Caspofungin Acetate-d4, CAS-d4; Linezolid-d3, LZD-d3; Meropenem-d6, MEM-d6; Piperacillin-d5, PER-d5; Voriconazole-d3, VCZ-d3).

Article Snippet: Caspofungin (CAS), cefmetazole (CMZ), linezolid (LZD), meropenem (MEM), imipenem (IPM), tigecycline (TIG), linezolid-d3 (LZD-d3), piperacillin-d5 (PRL-d5), voriconazole-d3 (VCZ-d3), meropenem-d6 (MEM-d6), and caspofungin acetate-d4 (CAS-d4) were obtained from Toronto Research Chemicals Inc. (Toronto, Canada).

Techniques:

Journal: bioRxiv

Article Title: Mitochondrial cardiolipin sequestration of caspofungin underlies Cryptococcus neoformans inherent resistance and may contribute to cardiotoxicity

doi: 10.64898/2026.01.20.700633

Figure Lengend Snippet: A: Chemical structure of caspofungin with marked positions utilized for derivatization with fluorescein (F-) and BDP 576/589 (BD-); amine groups (red); homo tyrosine (green). B: Determination of MIC for C. albicans C : and for C. neoformans D : Cell survival assay performed for cells treated with caspofungin (black) and its fluorescent derivatives – BD-CSF (red) and F-CSF (green). E : Spectral characterization of BD-CSF fluorescence bound to Cryptococcus cells following sequential treatment with CSF (blue) or BD-CSF (red), followed by either the same derivative (solid line) or the alternate derivative (dashed line).

Article Snippet: Briefly, the BD-CSF derivative of caspofungin (Biosynth International, Inc. cat# FC16269) was produced by incubating BDP® 576/589-succinimidate (Lumiprobe, cat# 2G420) with pure caspofungin in the presence of triethylamine as a proton acceptor in DMF.

Techniques: Derivatization, Clonogenic Cell Survival Assay, Fluorescence

Journal: bioRxiv

Article Title: Mitochondrial cardiolipin sequestration of caspofungin underlies Cryptococcus neoformans inherent resistance and may contribute to cardiotoxicity

doi: 10.64898/2026.01.20.700633

Figure Lengend Snippet: A: Representative wide field images of wild-type C. neoformans cells treated with BD-CSF (red) prior (top) and after (bottom) staining with NAO (green). Scale bar within each image marks 1µm length. B: Decrease in BD-CSF fluorescence following NAO treatment C: Decreased NAO uptake for cells pre-treated with BD-CSF in comparison with untreated cells D: Chemical structures of CSF (1) and NAO (2) both of which contain chemically similar lipid moieties. Chemical structure of 18:1 Cardiolipin (3) E: Representative isothermal titration calorimetry binding isotherm showing two-site binding between caspofungin (CSF) and cardiolipin (CL).

Article Snippet: Briefly, the BD-CSF derivative of caspofungin (Biosynth International, Inc. cat# FC16269) was produced by incubating BDP® 576/589-succinimidate (Lumiprobe, cat# 2G420) with pure caspofungin in the presence of triethylamine as a proton acceptor in DMF.

Techniques: Staining, Fluorescence, Comparison, Isothermal Titration Calorimetry, Binding Assay

Journal: bioRxiv

Article Title: Mitochondrial cardiolipin sequestration of caspofungin underlies Cryptococcus neoformans inherent resistance and may contribute to cardiotoxicity

doi: 10.64898/2026.01.20.700633

Figure Lengend Snippet: A: Schematic model of caspofungin distribution between its intended target - Fks1, and the off-site target mitochondrial cardiolipin implicating mitochondria are major sequesters of the available drug. B: Experimental design illustrating how pre-saturation of cardiolipin sites with the cardiolipin specific dye-NAO (green) increases the effective CSF concentration at its intended target, Fks1 C: Representative images of cells pre-treated with NAO prior to BD-CSF treatment showing increased plasma membrane localization of the drug. D: Viability assay of wild-type C. neoformans (gray) treated with CSF (blue) or BD-CSF (red), with or without NAO pre-treatment (green frame). After a cumulative 3h NAO pre-treatment followed by exposure to 10µM caspofungin (CSF) an 89-fold reduction in viability is observed, while NAO pre-treatment followed by 10 µM BD-CSF led to a 31-fold reduction, relative to the untreated control.

Article Snippet: Briefly, the BD-CSF derivative of caspofungin (Biosynth International, Inc. cat# FC16269) was produced by incubating BDP® 576/589-succinimidate (Lumiprobe, cat# 2G420) with pure caspofungin in the presence of triethylamine as a proton acceptor in DMF.

Techniques: Concentration Assay, Clinical Proteomics, Membrane, Viability Assay, Control

Journal: iScience

Article Title: Alexidine is a TAZ-specific small-molecule inhibitor that suppresses breast cancer invasion and metastasis

doi: 10.1016/j.isci.2025.114116

Figure Lengend Snippet: Alexidine effectively disrupts TAZ-TEAD interaction in vivo (A) The effect on the interaction of TAZ and TEAD biosensor in HEK293T cells treated with either alexidine, caspofungin, VT104, or DMSO control with the indicated concentration for 48 h. The TAZ-TEAD binding was detected by the presence of His-TEAD after FLAG-TAZ pull-down. The relative TEAD to TAZ ratio compared to the untreated sample was calculated through densitometry analysis in ImageJ. (B) The inhibitory effect of alexidine at different concentrations for 24 h on endogenous TAZ and TEAD binding in MDA-MB-231. The interaction of endogenous YAP/TAZ and TEAD proteins was monitored through co-immunopreciating with TEAD and YAP/TAZ using anti-YAP/TAZ antibody. Normal rabbit IgG was used as a coIP negative control. The TEAD to YAP/TAZ ratio was measured compared to the untreated control.

Article Snippet: Caspofungin Acetate , TargetMol , Cat# T1799; PubChem CID: 16119813.

Techniques: In Vivo, Control, Concentration Assay, Binding Assay, Negative Control